| Pharmaceutical Information |
| Drug Name |
Bevacizumab |
| Drug ID |
BADD_D00268 |
| Description |
There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells.[A192939,A192837,A192891,A193275] VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.[A192834,A192888,A192837,A192891,A192894]
In 2004, bevacizumab (Avastin) gained FDA approval for specific types of cancer, and became the first antiangiogenic agent introduced to the market.[A193272,A193275] It is a humanized monoclonal IgG antibody, and inhibits angiogenesis by binding and neutralizing VEGF-A.[A192888,A192939] Bevacizumab is generally indicated for use in combination with different chemotherapy regimens which are specific to the type, severity, and stage of cancer.[L12648]
Interestingly, researchers have identified higher VEGF expression in patients with COVID-19, which may contribute to lung pathologies including acute respiratory syndrome (ARDS) and acute lung injury (ALI).[L12699] As such, bevacizumab is being investigated for the treatment of lung complications associated with severe cases of COVID-19.[L12699] |
| Indications and Usage |
As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer; epithelial ovarian cancer; and fallopian tube cancer.[L12648] It can also be used to treat recurrent glioblastoma.[L12648]
Interestingly, bevacizumab is currently under investigation for the treatment of COVID-19 complications including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).[L12699] |
| Marketing Status |
approved; investigational |
| ATC Code |
L01FG01; S01LA08 |
| DrugBank ID |
DB00112
|
| KEGG ID |
D06409
|
| MeSH ID |
D000068258
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D04KBL
|
| NDC Product Code |
50242-061; 58394-095; 63552-113; 63552-114; 50242-060; 50242-059; 50242-160 |
| UNII |
2S9ZZM9Q9V
|
| Synonyms |
Bevacizumab | Mvasi | Bevacizumab-awwb | Bevacizumab awwb | Avastin |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
216974-75-3 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
